Nofinity Logo
Onboarding

Welcome to Nofinity

Your premium hub to transform hours of YouTube video into concise, 5-minute text summaries. Build your custom expert feed!

1. Skip the Video

Save hours of watching. Read compact, AI-powered key takeaways in a premium magazine layout – completely ad-free.

2. Custom Feed

Subscribe to top experts in the Explore area to curate your personal, dynamically updating video feed.

3. Suggest Channels

Propose new YouTube channels. Once approved, our system automatically ingests and summarizes new uploads.

Latest Analyses(7)

Add 10–20 Years of Youth With Gene Therapy | Dr. Noah Davidsohn
Modern Healthspan|01. Sept.

Add 10–20 Years of Youth With Gene Therapy | Dr. Noah Davidsohn

Dr. Noah Davidsohn on Gene Therapy for Age Reversal

Dr. Noah Davidsohn, CSO of Rejuvenate Bio, discusses two main therapeutic approaches: FGF21 gene therapy and epigenetic reprogramming with OSK.

FGF21 Gene Therapy for Dogs and Humans

  • Animal health program: Combination of anti-TGF-beta1 (antibody) and overexpression of FGF21. A single 10-minute infusion extends the lifespan of dogs with mitral valve disease by 1–2 years (equivalent to ~10–14 human years). The therapy works systemically; the liver produces the proteins. Conditional approval for dogs is expected around 2028.
  • Human program: FGF21 (the "starvation hormone") improves metabolism, heart function, and has anti-inflammatory effects. A single injection provides benefits for at least a decade. Human clinical trials are imminent (after one primate study and one GMP batch).

Epigenetic Reprogramming with OSK

  • Study in old mice (124 weeks, equivalent to ~80 human years): Three-factor reprogramming (Oct4, Sox2, Klf4 – without c-Myc) doubled the remaining lifespan and reversed the frailty index. The mice looked healthier and younger.
  • Mechanism: Partial reprogramming via cyclic activation (using antibiotic in water). Cells do not become full stem cells but rejuvenate epigenetically.
  • Safety: No tumor formation because c-Myc is omitted and the AAV vectors do not integrate into the genome. Any cancerous clone would lose the therapeutic DNA through cell division.

Outlook and Costs

  • Dr. Davidsohn estimates that first clinical applications are about two years away, with multiple different approaches available in five years.
  • Manufacturing costs are around $2,000 per dose for humans – an investment that pays off with 10–20 extra healthy years.
  • Rejuvenate Bio offers public investment opportunities via WeFunder (wefunder.com/rejuvenatebio).

Conclusion

The combination of one-time FGF21 gene therapy and cyclic OSK reprogramming promises significant extension of healthy lifespan – at affordable cost and with a strong safety profile.